Delivery Order SPE2DB20D3505-SPE2DB26FYBWF
- Not listed
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Yonsa 125 mg tablets (120-count units) valued at $4,542.74. This firm fixed-price, competitively awarded contract has an ultimate completion date of September 23, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child delivery order under a larger contract vehicle,...
- The Defense Logistics Agency awarded a $2,271.36 delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Yonsa 125 mg tablets (120 count). The contract is a firm fixed-price delivery order with a completion date of September 17, 2025, and represents a non-competitive set-aside award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of YONSA 125 mg tablets (120-count units) with a ceiling value of $2,271.36 and a firm fixed price structure. This non-set-aside delivery order is scheduled for completion by September 29, 2025, and will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a single delivery order issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 24, 2025, for the supply of Yonsa 125 mg tablets (120 count) with a firm fixed price of $2,271.36 and an ultimate completion date of October 16, 2025. This is a competitively awarded, non-set-aside delivery order executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion prime vendor agreement running through December 2026. The...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 10, 2025, for the supply of Yonsa 125 mg tablets (120-count units) with a contract ceiling value of $4,542.74 and a firm fixed price structure. The delivery order, which represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (valued at $999,999,999.00 through December 2026), is scheduled for completion by July 2, 2025. The contract was...
- The Defense Logistics Agency awarded a delivery order valued at $4,542.74 to AmerisourceBergen Drug Corp for 120 tablets of Yonsa 125 mg, a pharmaceutical product. The contract, awarded on August 12, 2025, carries a firm fixed-price structure with an ultimate completion date of September 3, 2025. This delivery order was competitively awarded with no set-aside designation and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. This delivery order represents...
- The Defense Logistics Agency awarded a $2,271.36 delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Yonsa 125 mg tablets (120 count). This is a firm fixed price, competitively awarded contract with no set-aside designation, scheduled for completion by September 23, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting military and...
- The Defense Logistics Agency awarded a delivery order valued at $2,271.36 to AmerisourceBergen Drug Corp for the supply of Yonsa 125 mg tablets (120-count units). This contract, issued on March 18, 2025, with an ultimate completion date of April 8, 2025, operates under a firm fixed-price structure with no set-aside designation. The award represents a competitive procurement action, reflecting the vendor's established capability to meet federal pharmaceutical supply requirements....
- The Defense Logistics Agency awarded a delivery order valued at $9,085.44 to AmerisourceBergen Drug Corp for 120 tablets of Yonsa 125 mg, a pharmaceutical product supporting military healthcare needs. This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 2, 2025, and represents a child contract under AmerisourceBergen's larger indefinite delivery contract vehicle with DLA. The place of performance is AmerisourceBergen's corporate office location...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,814.08 to AmerisourceBergen Drug Corp for the supply of Yonsa 125 mg tablets (120-count units) on September 24, 2025, with completion targeted for October 16, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's larger Indefinite...
- SPE2DB20D3505Indefinite Delivery Contract
- SPE2DB20D3505-SPE2DB26FYBWFDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 23, 2025, for the supply of Yonsa 125 mg tablets (120 count) with a ceiling value of $2,271.36. This competitively awarded, non-set-aside contract employs firm fixed-price pricing and is scheduled for completion by November 14, 2025. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania serves as the place of performance for this pharmaceutical delivery order. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen maintains an extensive portfolio of delivery orders supporting military healthcare systems and the Defense Health Agency through the DLA Medical Supply Chain. The company's demonstrated capability to fulfill federal pharmaceutical requirements through open competition is evidenced by its consistent award of non-set-aside contracts across a broad range of therapeutic domains and product categories.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.3k | 10/23/25 |